

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Bulletin from the extraordinary general meeting on March 28, 2022, in SynAct Pharma AB

Today, on March 28, 2022, an extraordinary general meeting was held in SynAct Pharma AB. The meeting was held only by advance voting (postal vote) in accordance with temporary legislation. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority of votes.

Election of new board member and remuneration for the new board member

The meeting resolved, in accordance with the proposal from the Nomination Committee, to elect Kerstin Hasselgren as new ordinary board member for the time period up until the end of the next annual general meeting alongside the board members elected at the annual general meeting held on May 21, 2021.

The meeting further resolved, in accordance with the proposal from the Nomination Committee, that board remuneration shall be paid with SEK 33,000 to Kerstin Hasselgren for the time period up until the end of the next annual general meeting (corresponding to a yearly remuneration of SEK 200,000). In addition thereto, a separate remuneration of SEK 17,000 shall be paid to Kerstin Hasselgren in her capacity as Chairman of the Audit Committee for the time period up until the end of the next annual general meeting (corresponding to a yearly remuneration of SEK 100,000).

Lund on March 28, 2022

SynAct Pharma AB (publ)

The information was submitted, through the agency of the contact person below, for publication at 14:00 CET on March 28, 2022.

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen

CEO, SynAct Pharma AB

Phone: +45 28 44 75 67

Mail: joo@synactpharma.com

Thomas Jonassen

CSO, SynAct Pharma AB

Phone: +45 40 15 66 69

Mail: tj@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com.